Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.130
-0.010 (-0.87%)
Jun 3, 2026, 9:35 AM EDT - Market open
Alzamend Neuro Employees
As of January 31, 2026, Alzamend Neuro had 6 total employees, including 4 full-time and 2 part-time employees. The number of employees decreased by 1 or -14.29% compared to the same quarter last year.
Employees
6
Change
-1
Growth
-14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,257,455
Market Cap
4.30M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jan 31, 2026 | 6 | -1 | -14.29% | 4 | 2 |
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| VivoSim Labs | 14 |
| Azitra | 13 |
| TransCode Therapeutics | 12 |
| Decoy Therapeutics | 11 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Galmed Pharmaceuticals | 6 |
| CDT Equity | 4 |
ALZN News
- 2 months ago - Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial - TheFly
- 2 months ago - Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - PRNewsWire
- 2 months ago - Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001 - TheFly
- 2 months ago - Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - PRNewsWire
- 2 months ago - Alzamend Neuro initiates Phase II trial of AL001 study - TheFly
- 2 months ago - Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - PRNewsWire
- 7 months ago - Alzamend Neuro completes clinical portion of Phase II clinical study of AL001 - TheFly
- 7 months ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire